ArticleBiomedical reports2026
Comparative cross-sectional study between conventional and IQOS smoking and impact on fatty acid-binding protein 4.
Article in Biomedical reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Smoking tobacco remains a leading global health threat, particularly in Jordan, where a notable portion of the population, including children, are smokers. Despite health campaigns, traditional smoking persists, prompting interest in the health impacts of alternatives such as heat-not-burn (HNB) devices such as 'I quit ordinary smoking' (IQOS). Examining biomarkers such as fatty acid-binding protein 4 (FABP4), a marker of early vascular and metabolic damage, may provide insight into the health outcomes of these smoking methods. The present study aimed to compare the effects of both traditional cigarette smoking and IQOS use on FABP4 levels. Venous blood samples from 204 participants (65 IQOS users, 75 conventional smokers and 64 non-smokers) were analyzed for complete blood count, alanine transaminase (ALT), C-reactive protein, superoxide dismutase (SOD) and FABP4 levels. Male cigarette smokers exhibited significantly elevated mean corpuscular volume compared with non-smokers (P=0.003), and IQOS smokers compared with non-smokers showed similar trends (P=0.035). ALT levels were significantly higher in IQOS smokers compared with both non-smokers (P<0.0001) and cigarette smokers (P=0.001). FABP4 levels were also highest in IQOS smokers, significantly surpassing both non-smokers (P<0.0001) and cigarette smokers (P=0.001). ALT and FABP4 were positively correlated (ρ=0.234, P=0.001). In the IQOS group, weight was positively correlated with hemoglobin, red blood cell count and FABP4 levels. Moreover, IQOS users who exercised had lower FABP4 levels compared with non-exercisers (P=0.001), indicating notable health marker differences associated with smoking habits, particularly among IQOS users. Smoking, whether through conventional cigarettes or alternative options such as IQOS, significantly affects blood composition, liver function indicated by high ALT and markers of oxidative stress, such as SOD. IQOS smoking significantly increases FABP4 levels, a marker of inflammation and tissue damage. To the best of our knowledge, the present study is the first to assess the impact of IQOS and smoking on FABP4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.